|
|
|
Innovative Partnerships
|
Advance Market Commitment (AMC): Preventing Pneumococcal Diseases
An Advance Market Commitment (AMC) is a new approach to public health funding designed to stimulate the development and manufacture of vaccines for developing countries.
Donors commit money to guarantee the price of vaccines once they have been developed, thus creating the potential for a viable future market. Decisions regarding which diseases to target, criteria for effectiveness, price and long-term availability are made in advance. The donor commitments provide vaccine manufacturers with the incentive they need to invest the considerable sums required to conduct research, train staff and build manufacturing facilities. In exchange, participating companies must guarantee to supply their vaccine for a period of 10 years at a pre-agreed low price (tail price).
By Gavi Alliance
|
 Building Partnerships and Financing Cooperation across Developing Countries: Trends and Opportunities for NGOs
The terms of reference of the United Nations non governmental organizations Informal Regional Network (UN-NGO-IRENE), mandates, inter alia, the establishment of a technology based system that facilitates interactive exchange at the regional and global level between the United Nations and non governmental organizations (NGOs) in consultative status with the Economic and Social Council (ECOSOC). In support of the above mentioned mandate, the NGO Branch, Department of Economic and Social Affairs, has developed a new web portal, entitled "Civil Society Best Practices Network" (BPN), allowing NGOs in consultative status with ECOSOC to share and promote Best Practices and success stories.
By UN-DESA NGO Branch in collaboration with Special Unit for South-South Cooperation of UNDP
|
|
The International Finance Facility for Immunisation (IFFIm)
In the developed world, protection from disease through immunisation is taken for granted. But every year in poorer countries, some 24 million children miss out on vaccinations against the most common diseases, making them vulnerable to sickness, disability and death.
By Gavi Alliance
|
|
The Medicines Patent Pool Initiative
UNITAID's mission is to contribute to scaling up access to treatment for HIV/AIDS, malaria and tuberculosis, primarily for people in low-income countries, by leveraging price reductions for quality diagnostics and medicines and accelerating the pace at which these are made available.
By UNITAID, An Innovative Financing Mechanism
|
|
UNFPA's Developmental Approach: Reaching Common Ground by engaging Faith-Based Organisations as Agents of Change
The United Nations Population Fund (UNFPA) regards culture as a critical component of development and religion as an important aspect of cultural landscape. Because of the prominent role that religion plays in so many communities around the world, religious leaders, faith-based organizations (FBOs) and faith-based service delivery networks often have the potential to be among the most influential agents of change. FBOs provide anywhere between 30-70% of the health services in many parts of the developing world. From 2006-2008, UNFPA undertook a mapping of it?s partnerships with faith-based organizations working on the MDGs and the International Conference on Population and Development (ICPD) Programme of Action. The resulting publication, entitled ?Culture Matters: A Legacy of Engaging Faith-Based Organizations? was outlined however 100 UNFPA Country Offices partnered with over 75 different FBOs around the world.
By United Nations Population Fund (UNFPA)
|
|
Health Promotion and Global Partnerships: WOMEN AND DIABETES
While much attention has been paid to communicable diseases on the international level, the adverse affects of chronic and noncommunicable diseases (NCDs) on populations around the world are often overlooked. This is particularly true when addressing gender and NCDs. Women are especially affected by NCDs in both developing and developed nations. An example of one such disease is diabetes.
By The Global Alliance for Women's Health
|
|
Medicines for Malaria Venture
Medicines for Malaria Venture, a not-for-profit public-private partnership, was established as a foundation in Switzerland in 1999. It is dedicated to reducing the burden of malaria in disease-endemic countries by discovering, developing and facilitating delivery of new, effective and affordable antimalarial drugs. MMV?s vision is a world in which these innovative medicines will cure and protect the vulnerable and under-served populations at risk of malaria and contribute to the achievement of the MDGs 4 and 6. Malaria eradication is MMV's critical long-term goal.
By Medicines for Malaria Venture
|
|
The LEAP Platform (Leishmaniasis in East Africa Platform) for Leishmaniasis
The LEAP Platform (Leishmaniasis in East Africa Platform) is a regional clinical research network that brings together experts from leishmaniasis-endemic countries in East Africa.
Founded in Khartoum, Sudan, in 2003, by the non profit R organisation Drugs for neglected Diseases Initiative (DNDI), the LEAP Platform incorporates partner institutions from across the spectrum of clinical research and disease control organizations working in leishmaniasis.
By DNDi Drugs for Neglected Diseases
|
|
Case Studies for Global Health
The Bill Gates Foundation, World Health Organization-based Special Programme for Research and Training in Tropical Diseases (TDR), International AIDS Vaccine Initiative (IAVI), Association of University Technology Managers (AUTM) and Global Health Progress (GHP) have joined together to prepare a set of multi-sector case studies to identify ways in which key stakeholders are addressing global health concerns. These studies will describe existing or planned collaborative relationships, projects and transactions with the aim of sharing lessons learned with the wider global health community.
By Global Health Progress
|
|
Partnership for Disease Control Initiatives (PDCI) - Neglected Tropical Disease Control in Uganda
PDCI is a coalition of NGOs, pharmaceutical companies, WHO, donors, and other partners collaborating on disease-specific drug donation programs for neglected tropical diseases (NTDs). PDCI provides a forum for stakeholders to share best practices, information, and experiences and to discuss tools and strategies to improve access to essential medicines for populations affected by NTDs. In Uganda for example, drugs are being donated for mass chemotherapy by PDCI members and partners to control and/or eliminate six NTDs.
By Partnership for Disease Control Initiatives
|
|
Partnerships to Increase R for Diseases of the Developing World
Discovery and development of treatments and preventive technologies targeted at the so-called ?Neglected Diseases? of the developing world have long posed vexing scientific and regulatory challenges. Since the beginning of this decade, the world?s R -based companies --represented by the International Federation of Pharmaceutical Manufacturers and Associations-- have significantly stepped up pharmaceutical and vaccine R programs directed at Diseases of the Developing World (DDW). This positive trend had been encouraged by broad use of partnership approaches, with ad-hoc product development partnerships bringing together private R -based pharmaceutical companies, universities and government research laboratories.
By International Federation of Pharmaceutical Manufacturers (IFPMA)
|
|
|
|
